These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 31834436)
1. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Tomimaru Y; Eguchi H; Iwagami Y; Akita H; Noda T; Gotoh K; Kobayashi S; Nagano H; Mori M; Doki Y Cancer Chemother Pharmacol; 2020 Mar; 85(3):537-545. PubMed ID: 31834436 [TBL] [Abstract][Full Text] [Related]
2. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Tomimaru Y; Eguchi H; Satoh T; Tomokuni A; Asaoka T; Wada H; Marubashi S; Ogawa K; Takehara T; Mori M; Doki Y; Nagano H Jpn J Clin Oncol; 2015 Apr; 45(4):343-8. PubMed ID: 25589454 [TBL] [Abstract][Full Text] [Related]
3. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119 [TBL] [Abstract][Full Text] [Related]
5. A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. Eguchi H; Takeda Y; Takahashi H; Nakahira S; Kashiwazaki M; Shimizu J; Sakai D; Isohashi F; Nagano H; Mori M; Doki Y Ann Surg Oncol; 2019 Dec; 26(13):4498-4505. PubMed ID: 31440928 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063 [TBL] [Abstract][Full Text] [Related]
7. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Tomihara H; Eguchi H; Yamada D; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y Surg Today; 2017 Feb; 47(2):218-226. PubMed ID: 27586014 [TBL] [Abstract][Full Text] [Related]
8. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer. Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035 [TBL] [Abstract][Full Text] [Related]
9. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence. Takahashi H; Akita H; Gotoh K; Kobayashi S; Marubashi S; Miyoshi N; Sugimura K; Motoori M; Kishi K; Noura S; Fujiwara Y; Ohue M; Ohigashi H; Yano M; Sakon M; Ishikawa O Surgery; 2015 Mar; 157(3):484-95. PubMed ID: 25444512 [TBL] [Abstract][Full Text] [Related]
10. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991 [TBL] [Abstract][Full Text] [Related]
11. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S; Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735 [TBL] [Abstract][Full Text] [Related]
12. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy. Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764 [TBL] [Abstract][Full Text] [Related]
13. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Hirata T; Teshima T; Nishiyama K; Ogawa K; Otani K; Kawaguchi Y; Konishi K; Tomita Y; Takahashi H; Ohigashi H; Ishikawa O Radiother Oncol; 2015 Jan; 114(1):122-7. PubMed ID: 25614389 [TBL] [Abstract][Full Text] [Related]
14. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476 [TBL] [Abstract][Full Text] [Related]
15. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Takahashi H; Ohigashi H; Gotoh K; Marubashi S; Yamada T; Murata M; Ioka T; Uehara H; Yano M; Ishikawa O Ann Surg; 2013 Dec; 258(6):1040-50. PubMed ID: 23799421 [TBL] [Abstract][Full Text] [Related]
16. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence. Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960 [TBL] [Abstract][Full Text] [Related]